1. Pink Sheet
  2. >>Drug Safety

Abuse Deterrent Opioids: Which Studies Will Show Real World Effect?

 
• By Brenda Sandburg

Experts suggest ways to assess impact of abuse deterrent opioid formulations at US FDA scientific workshop; showing statistical significance may not be possible.

Opioid abuse epidemic concept

FDA convened a diverse panel of experts to help piece together a "mosaic picture" of studies that might show whether opioids with abuse deterrent properties work in the real world. While the panelists didn't come up with definitive answers, they sketched ideas that may be used to improve the collection and analysis of data.

The July 10-11 scientific workshop focused on the current data resources used to investigate abuse deterrent formulations of opioids, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

‘Prices Can Remain Contaminated Indefinitely’: Advanz Brushed Aside On UK Liothyronine Appeal

 
• By Dean Rudge

England’s Court of Appeal has upheld a Competition Appeal Tribunal’s 2023 finding that Advanz and its former owner Cinven abused their dominant position in the UK market for liothyronine tablets by charging prices that were many orders of magnitude higher than the benchmark for fair pricing.

New EU Filings

 
• By Neena Brizmohun

Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

 
• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.